|
1
|
Chow WH, Dong LM and Devesa SS:
Epidemiology and risk factors for kidney cancer. Nat Rev Urol.
7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Martinez-Salamanca JI, Huang WC, Millan I,
Bertini R, Bianco FJ, Ciancio G, Hernández C, Herranz F, Haferkamp
A, et al: Prognostic impact of the 2009 UICC/AJCC TNM staging
system for renal cell carcinoma with venous extension. Eur Urol.
59:120–127. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fang J, Feng Q, Ketel CS, Wang H, Cao R,
Xia L, Erdjument-Bromage H, Tempst P, Simon JA and Zhang Y:
Purification and functional characterization of SET8, a nucleosomal
histone H4-lysine 20-specific methyltransferase. Curr Biol.
12:1086–1099. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nishioka K, Rice JC, Sarma K,
Erdjument-Bromage H, Werner J, Wang Y, Chuikov S, Valenzuela P,
Tempst P, Steward R, et al: PR-Set7 is a nucleosome-specific
methyltransferase that modifies lysine 20 of histone H4 and is
associated with silent chromatin. Mol Cell. 9:1201–1213. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oda H, Okamoto I, Murphy N, Chu J, Price
SM, Shen MM, Torres Padilla ME, Heard E and Reinberg D:
Monomethylation of histone H4-lysine 20 is involved in chromosome
structure and stability and is essential for mouse development. Mol
Cell Biol. 29:2278–2295. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Houston SI, McManus KJ, Adams MM, Sims JK,
Carpenter PB, Hendzel MJ and Rice JC: Catalytic function of the
PR-Set7 histone H4 lysine 20 monomethyltransferase is essential for
mitotic entry and genomic stability. J Biol Chem. 283:19478–19488.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jorgensen S, Elvers I, Trelle MB, Menzel
T, Eskildsen M, Jensen ON, Helleday T, Helin K and Sorensen CS: The
histone methyltransferase SET8 is required for S-phase progression.
J Cell Biol. 179:1337–1345. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Abbas T, Shibata E, Park J, Jha S, Karnani
N and Dutta A: CRL4(Cdt2) regulates cell proliferation and histone
gene expression by targeting PR-Set7/Set8 for degradation. Mol
Cell. 40:9–21. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Centore RC, Havens CG, Manning AL, Li JM,
Flynn RL, Tse A, Jin J, Dyson NJ, Walter JC and Zou L:
CRL4(Cdt2)-mediated destruction of the histone methyltransferase
Set8 prevents premature chromatin compaction in S phase. Mol Cell.
40:22–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu S, Wang W, Kong X, Congdon LM, Yokomori
K, Kirschner MW and Rice JC: Dynamic regulation of the PR-Set7
histone methyltransferase is required for normal cell cycle
progression. Genes Dev. 24:2531–2542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo Z, Wu C, Wang X, Wang C, Zhang R and
Shan B: A polymorphism at the miR-502 binding site in the
3′-untranslated region of the histone methyltransferase SET8 is
associated with hepatocellular carcinoma outcome. Int J Cancer.
131:1318–1322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang F, Sun L, Li Q, Han X, Lei L, Zhang H
and Shang Y: SET8 promotes epithelial-mesenchymal transition and
confers TWIST dual transcriptional activities. EMBO J. 31:110–123.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song F, Zheng H, Liu B, Wei S, Dai H,
Zhang L, Calin GA, Hao X, Wei Q, Zhang W and Chen K: An
miR-502-binding site single-nucleotide polymorphism in the
3′-untranslated region of the SET8 gene is associated with early
age of breast cancer onset. Clin Cancer Res. 15:6292–6300. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu N, Huangyang P, Yang X, Han X, Yan R,
Jia H, Shang Y and Sun L: microRNA-7 suppresses the invasive
potential of breast cancer cells and sensitizes cells to DNA
damages by targeting histone methyltransferase SET8. J Biol Chem.
288:19633–19642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu B, Zhang X, Song F, Zheng H, Zhao Y,
Li H, Zhang L, Yang M, Zhang W and Chen K: MiR-502/SET8 regulatory
circuit in pathobiology of breast cancer. Cancer Lett. 376:259–267.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mosallayi M, Simonian M, Khosravi S,
Salehi AR, Khodadoostan M, Sebghatollahi V, Baradaran A and Salehi
R: Polymorphism (rs16917496) at the miR-502 binding site of the
lysine methyltransferase 5A (SET8) and Its correlation with
colorectal cancer in iranians. Adv Biomed Res. 6:772017.PubMed/NCBI
|
|
18
|
Liao T, Wang YJ, Hu JQ, Wang Y, Han LT, Ma
B, Shi RL, Qu N, Wei WJ, Guan Q, et al: Histone methyltransferase
KMT5A gene modulates oncogenesis and lipid metabolism of papillary
thyroid cancer in vitro. Oncol Rep. 39:2185–2192. 2018.PubMed/NCBI
|
|
19
|
Wang C, Wu J, Zhao Y and Guo Z: miR-502
medaited histone methyltransferase SET8 expression is associated
with outcome of esophageal squamous cell carcinoma. Sci Rep.
6:329212016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Benamar M, Guessous F, Du K, Corbett P,
Obeid J, Gioeli D, Slingluff CL Jr and Abbas T: Inactivation of the
CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies
the therapeutic efficacy of pevonedistat in melanoma. EBioMedicine.
10:85–100. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yao L, Li Y, Du F, Han X, Li X, Niu Y, Ren
S and Sun Y: Histone H4 Lys 20 methyltransferase SET8 promotes
androgen receptor-mediated transcription activation in prostate
cancer. Biochem Biophys Res Commun. 450:692–696. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang C, Guo Z, Wu C, Li Y and Kang S: A
polymorphism at the miR-502 binding site in the 3′ untranslated
region of the SET8 gene is associated with the risk of epithelial
ovarian cancer. Cancer Genet. 205:373–376. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using realtime quantitative PCR and
the 2(Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee TI, Johnstone SE and Young RA:
Chromatin immunoprecipitation and microarray-based analysis of
protein location. Nat Protoc. 1:729–748. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Janzen NK, Kim HL, Figlin RA and
Belldegrun AS: Surveillance after radical or partial nephrectomy
for localized renal cell carcinoma and management of recurrent
disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Myszczyszyn A, Czarnecka AM, Matak D,
Szymanski L, Lian F, Kornakiewicz A, Bartnik E, Kukwa W, Kieda C
and Szczylik C: The role of hypoxia and cancer stem cells in renal
cell carcinoma pathogenesis. Stem Cell Rev. 11:919–943. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Krishnamachary B, Zagzag D, Nagasawa H,
Rainey K, Okuyama H, Baek JH and Semenza GL: Hypoxia-inducible
factor-1-dependent repression of E-cadherin in von Hippel- Lindau
tumor suppressor-null renal cell carcinoma mediated by TCF3,
ZFHX1A, and ZFHX1B. Cancer Res. 66:2725–2731. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Russell RC and Ohh M: The role of VHL in
the regulation of E-cadherin: A new connection in an old pathway.
Cell Cycle. 6:56–59. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Harten SK, Shukla D, Barod R, Hergovich A,
Balda MS, Matter K, Esteban MA and Maxwell PH: Regulation of renal
epithelial tight junctions by the von Hippel-Lindau tumor
suppressor gene involves occludin and claudin 1 and is independent
of E-cadherin. Mol Biol Cell. 20:1089–1101. 2009. View Article : Google Scholar : PubMed/NCBI
|
